CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice

Journal of Clinical Investigation

Volumn 117, Issue 12, 2007, Pages 3753-3764

  Tang, Xiuwei ^a   Zhu, Yucui ^a   Han, Lydia ^a   Kim, Arianna L ^a   Kopelovich, Levy ^b   Bickers, David R ^a   Athar, Mohammad ^a,c  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ADENOSINE DIPHOSPHATE RIBOSE; CASPASE 3; CYCLIN D1; CYTOCHROME C; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P21; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MALE; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SKIN CARCINOGENESIS; ULTRAVIOLET B RADIATION; WILD TYPE;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYCLINS; CYTOCHROMES C; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; MALE; MICE; MICE, INBRED HRS; MITOCHONDRIA; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MUTATION; NEOPLASMS, RADIATION-INDUCED; POLY(ADP-RIBOSE) POLYMERASES; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN TRANSPORT; PYRIMIDINES; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 36849084779     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI32481     Document Type: Article

References (61)

1. Vogelstein, B., and Kinzler, K.W. 2004. Cancer genes and the pathways they control. Nat. Med. 10:789-799.
2. Vogelstein, B., Lane, D., and Levine, A.J. 2000. Surfing the p53 network. Nature. 408:307-310.
3. van Kranen, H.J., and de Gruijl, F.R. 1999. Mutations in cancer genes of UV-induced skin tumors of hairless mice. J. Epidemiol. 9:S58-S65.
4. Phan, T.A., Halliday, G.M., Barnetson, R.S., and Damian, D.L. 2006. Spectral and dose dependence of ultraviolet radiation-induced immunosuppression. Front. Biosci. 11:394-411.
5. D'Errico, M., Lemma, T., Calcagnile, A., Santis, L.P.D., and Dogliotti, E. 2007. Cell type and DNA damage specific response of human skin cells to environmental agents. Mutat. Res. 614:37-47.
6. Mitchell, D.L., and Nairn, R.S. 1989. The biology of the (6-4) photoproduct. Photochem. Photobiol. 49:805-819.
7. Ehrhart, J.C., Gosselet, F.P., Culerrier, R.M., and Sarasin, A. 2003. UVB-induced mutations in human key gatekeeper genes governing signalling pathways and consequences for skin tumourigenesis. Photochem. Photobiol. Sci. 2:825-834.
8. Giglia-Mari, G., and Sarasin, A. 2003. TP53 mutations in human skin cancers. Hum. Mutat. 21:217-228.
9. van Kranen, H.J., et al. 2005. Dose-dependent effects of UVB-induced skin carcinogenesis in hairless p53 knockout mice. Mutat. Res. 571:81-90.
10. Nelson, M.A., et al. 1994. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett. 85:23-29.
11. Cleaver, J.E., and Crowley, E. 2002. UV damage, DNA repair and skin carcinogenesis. Front. Biosci. 7:d1024-d1043.
12. Kim, A.L., et al. 1999. Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J. Biol. Chem. 274:34924-34931.
13. El-Deiry, W.S. 2001. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 8:1066-1075.
14. el-Deiry, W.S. 1998. Regulation of p53 downstream genes. Semin. Cancer. Biol. 8:345-357.
15. Hupp, T.R., Sparks, A., and Lane, D.P. 1995. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell. 83:237-245.
16. Roth, J.A., and Grammer, S.F. 2003. Tumor suppressor gene therapy. Methods Mol. Biol. 223:577-598.
17. Marx, J. 2007. Oncology. Recruiting the cell's own guardian for cancer therapy. Science. 315:1211-1213.
18. Blagosklonny, M.V. 2002. P53: an ubiquitous target of anticancer drugs. Int. J. Cancer. 98:161-166.
19. Foster, B.A., Coffey, H.A., Morin, M.J., and Rastinejad, F. 1999. Pharmacological rescue of mutant p53 conformation and function. Science. 286:2507-2510.
20. Wang, W., Takimoto, R., Rastinejad, F., and El-Deiry, W.S. 2003. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol. Cell. Biol. 23:2171-2181.
21. Wang, W., Kim, S.H., and El-Deiry, W.S. 2006. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc. Natl. Acad. Sci. U. S. A. 103:11003-11008.
22. Wang, W., Rastinejad, F., and El-Deiry, W.S. 2003. Restoring p53-dependent tumor suppression. Cancer Biol. Ther. 2:S55-S63.
23. Bickers, D.R., and Athar, M. 2000. Novel approaches to chemoprevention of skin cancer. J. Dermatol. 27:691-695.
24. Starcher, B., and Conrad, M. 1995. A role for neutrophil elastase in solar elastosis. Ciba Found. Symp. 192:338-346; discussion 346-347.
25. Takimoto, R., and Niitsu, Y. 2004. Tumor suppressor gene p53 and molecular targeting therapy [In Japanese]. Gan To Kagaku Ryoho. 31:1309-1313.
26. Bykov, V.J., Selivanova, G., and Wiman, K.G. 2003. Small molecules that reactivate mutant p53. Eur. J. Cancer. 39:1828-1834.
27. Reiss, M., et al. 1992. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines. Oncol. Res. 4:349-357.
28. Park, D.J., et al. 1994. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene. 9:1899-1906.
29. Ogawa, Y., et al. 2004. Reactive oxygen speciesproducing site in radiation-induced apoptosis of human peripheral T cells: involvement of lysosomal membrane destabilization. Int. J. Mol. Med. 13:69-73.
30. Smiley, S.T., et al. 1991. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc. Natl. Acad. Sci. U. S. A. 88:3671-3675.
31. Reers, M., Smith, T.W., and Chen, L.B. 1991. J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry. 30:4480-4486.
32. Di Lisa, F., et al. 1995. Mitochondrial membrane potential in single living adult rat cardiac myocytes exposed to anoxia or metabolic inhibition. J. Physiol. 486:1-13.
33. Chaoui, D., et al. 2006. JC-1, a sensitive probe for a simultaneous detection of P-glycoprotein activity and apoptosis in leukemic cells. Cytometry B Clin. Cytom. 70:189-196.
34. Erster, S., Mihara, M., Kim, R.H., Petrenko, O., and Moll, U.M. 2004. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol. Cell. Biol. 24:6728-6741.
35. Chipuk, J.E., and Green, D.R. 2006. Dissecting p53-dependent apoptosis. Cell Death Differ. 13:994-1002.
36. Chipuk, J.E., Maurer, U., Green, D.R., and Schuler, M. 2003. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell. 4:371-381.
37. Zhao, Y., et al. 2005. p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. Cancer Res. 65:3745-3750.
38. Marques-Santos, L.F., Coqueiro, V.M., and Rumjanek, V.M. 2006. Cyclosporin A does not protect the disruption of the inner mitochondrial membrane potential induced by potassium ionophores in intact K562 cells. Cell Biol. Int. 30:197-204.
39. Tay, V.K., et al. 2005. Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. Free Radic. Biol. Med. 39:949-959.
40. Levine, A.J., Momand, J., and Finlay, C.A. 1991. The p53 tumour suppressor gene. Nature. 351:453-456.
41. Leng, R.P., et al. 2003. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 112:779-791.
42. Duan, W., et al. 2006. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells. Exp. Cell Res. 312:3370-3378.
43. Kim, A.L., Athar, M., Bickers, D.R., and Gautier, J. 2002. Stage-specific alterations of cyclin expression during UVB-induced murine skin tumor development. Photochem. Photobiol. 75:58-67.
44. Kastan, M.B. 2007. Wild-type p53: tumors can't stand it. Cell. 128:837-840.
45. Ventura, A., et al. 2007. Restoration of p53 function leads to tumour regression in vivo. Nature. 445:661-665.
46. Xue, W., et al. 2007. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 445:656-660.
47. Bernal, F., Tyler, A.F., Korsmeyer, S.J., Walensky, L.D., and Verdine, G.L. 2007. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J. Am. Chem. Soc. 129:2456-2457.
48. Bykov, V.J., et al. 2002. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8:282-288.
49. Nahi, H., et al. 2004. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br. J. Haematol. 127:285-291.
50. Vassilev, L.T., et al. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 303:844-848.
51. Sausville, E.A., Burger, A.M., Becher, O.J., and Holland, E.C. 2006. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 66:3351-3354.
52. McDonald, E.R., 3rd, and El-Deiry, W.S. 2000. Cell cycle control as a basis for cancer drug development (review). Int. J. Oncol. 16:871-886.
53. Ho, C.K., and Li, G. 2005. Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis. Br. J. Dermatol. 153:900-910.
54. Luu, Y., Bush, J., Cheung, K.J., Jr., and Li, G. 2002. The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. Exp. Cell Res. 276:214-222.
55. Rippin, T.M., et al. 2002. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene. 21:2119-2129.
56. Takimoto, R., et al. 2002. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol. Ther. 1:47-55.
57. Wang, W., et al. 2005. Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol. Ther. 4:893-898.
58. Wang, W., and El-Deiry, W.S. 2004. Targeting p53 by PTD-mediated transduction. Trends Biotechnol. 22:431-434.
59. Wischhusen, J., Naumann, U., Ohgaki, H., Rastinejad, F., and Weller, M. 2003. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene. 22:8233-8245.
60. Luo, J.L., et al. 2001. UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sunexposed human skin. Cancer Res. 61:8158-8163.
61. Mihara, M., et al. 2003. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell. 11:577-590.